New Analysis Explains What Lilly’s ObesityWeek 2026 EloraTZP Results Add to the September Phase 2b Readout and What They Leave Unchanged

Nov 17, 2026

Eloralintide-Peptide.com Breaks Down Lilly's ObesityWeek 2026 EloraTZP Data and the First Participant-Reported Findings on Eloralintide. New analysis separates what changed at ObesityWeek from what did not: responder rates and exit-interview data are new, the headline weight-loss figures are not.

Los Angeles, United States, November 17, 2026 -- Los Angeles, CA – Eloralintide Peptide Research, an independent research resource covering the investigational amylin receptor agonist eloralintide, has published a plain-language breakdown of the data Eli Lilly presented at ObesityWeek 2026 in Washington, DC. The full analysis is available at https://eloralintide-peptide.com/eloralintide-obesityweek-2026/.

Lilly's presentations covered two sets of findings. The first was a group of new responder analyses from the 48-week Phase 2b trial of EloraTZP, the combination of eloralintide and tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes (NCT06603571). The second was the first patient-experience data from the eloralintide Phase 2 monotherapy trial (NCT06230523).

What the new analyses reported

  • Up to 60% of participants on the combination no longer met BMI criteria for obesity at 48 weeks.
  • Up to 77% reached normal blood sugar levels, with A1C falling by as much as 2.9 points.
  • In exit interviews from the monotherapy trial, 74% of eloralintide participants reported fewer food cravings and 52% reported less "food noise."
  • Among participants who drank alcohol at baseline, 41% reported drinking less.

What did not change

The analysis stresses that ObesityWeek produced no new average weight-loss results. The headline figures still come from the September 30, 2026 readout at EASD: 23.3% mean weight loss with eloralintide 9 mg plus tirzepatide 15 mg, against 14.8% with tirzepatide 15 mg alone.

It also flags the limits of the new material. The exit-interview findings are qualitative and self-reported, not trial endpoints. Tolerability remains the open question: 10.8% to 27.0% of participants on the combinations stopped treatment because of side effects, compared with 2.9% on tirzepatide alone. Lilly's Phase 3 program uses a single-injection co-formulation with a slower escalation schedule, and whether that lowers discontinuations will not be known until those trials read out.

"Responder rates make strong headlines, but they are a different cut of the same September data, not a new result," said the editorial team at Eloralintide-Peptide.com. "Our job is to show readers which numbers are new, which are self-reported, and which questions only Phase 3 can answer."

Neither eloralintide nor EloraTZP is approved by the FDA or any other regulator. The site will continue to track the program, including updates analysts expect at Lilly's Innovation Day on December 7, 2026.

Read more articles on eloralintide research, trial data and sourcing, including a look at how the compound is being discussed on reddit.

About Eloralintide Peptide Research

Eloralintide Peptide Research is an independent research resource focused on a single compound. It covers published clinical trials, sourcing checks and certificates of analysis, with figures linked to their original sources. The site is not affiliated with Eli Lilly and Company.

Disclaimer: Content is for research and informational purposes only and is not medical advice. Eloralintide is an investigational compound that has not been approved by the FDA or any other regulator. Clinical trial results describe the investigational drug studied and are not evidence about any vendor's product.

Contact Info:
Name: Benson Jamison
Email: Send Email
Organization: Eloralintide Peptide Research
Phone: 3105613389
Website: https://eloralintide-peptide.com/

Release ID: 89209868

In case of encountering any inaccuracies, problems, or queries arising from the content shared in this press release that necessitate action, or if you require assistance with a press release takedown, we urge you to notify us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be readily available to promptly address your concerns within 8 hours, resolving any identified issues diligently or guiding you through the necessary steps for removal. The provision of accurate and dependable information is our primary focus.

More News
MS Dhoni's CSK Career In Numbers: Five IPL Trophies, 5,439 Runs And Uncountable Memories
Nov 17, 2026
MS Dhoni's CSK Career In Numbers: Five IPL Trophies, 5,439 Runs And Uncountable Memories

MS Dhoni will no longer be seen in Chennai Super Kings' iconic yellow on the field, bat in hand or standing behind the stumps, as the franchise legend transitions from player to Team Mentor from the 2027 season onwards.

Crying Rory McIlroy's pain for his sick father: How golf superstar is driven on by his dad's double-lung transplant - after years of putting personal troubles aside to win
Nov 17, 2026
Crying Rory McIlroy's pain for his sick father: How golf superstar is driven on by his dad's double-lung transplant - after years of putting personal troubles aside to win

McIlroy was opening up about his father's serious health problems, revealing that Gerry had undergone a double-lung transplant in September as a 'last resort' after 18 months of ill health.

Mohammed Shami Takes Rs 2 Crore Pay Cut, Joins Former Champions Ahead Of IPL 2027 In Multi-Player Trade
Nov 17, 2026
Mohammed Shami Takes Rs 2 Crore Pay Cut, Joins Former Champions Ahead Of IPL 2027 In Multi-Player Trade

Veteran India pacer Mohammed Shami has moved from Lucknow Super Giants (LSG) to Rajasthan Royals (RR). Spinner M Siddharth has also joined RR, while Sam Curran has gone to LSG.

MS Dhoni retires as IPL player: Check season-wise earnings, how  ₹6.03 crore in 2008 grew to  ₹200.72 crore over 18 years
Nov 17, 2026
MS Dhoni retires as IPL player: Check season-wise earnings, how ₹6.03 crore in 2008 grew to ₹200.72 crore over 18 years

MS Dhoni has retired from the IPL as a player and will be Chennai Super Kings' team mentor from the 2027 season. Here is a look at the star player's earnings from 2008 to 2026.

IPL 2027 trade: Rajasthan Royals land Mohammed Shami for  ₹8 crore as Sam Curran heads to Lucknow Super Giants
Nov 17, 2026
IPL 2027 trade: Rajasthan Royals land Mohammed Shami for ₹8 crore as Sam Curran heads to Lucknow Super Giants

The trade addresses clear needs on both sides. Rajasthan Royals gain experienced Indian pace and spin options, while Lucknow Super Giants add overseas all-round utility.

Declan Rice agrees new five-year Arsenal contract: Star to join Bukayo Saka as Gunners' highest-paid player at over £350,000-per-week... with goalkeeper David Raya set to sign long-term deal to stay too
Nov 17, 2026
Declan Rice agrees new five-year Arsenal contract: Star to join Bukayo Saka as Gunners' highest-paid player at over £350,000-per-week... with goalkeeper David Raya set to sign long-term deal to stay too

The England midfielder is expected to sign the new contract soon, which is set to put him alongside Bukayo Saka as Arsenal's top earner. Saka is on a deal worth over £350,000 a week.

IPL 2027 Retention LIVE Updates: MS Dhoni Retires. Mohammed Shami Takes Huge Paycut In RR
Nov 17, 2026
IPL 2027 Retention LIVE Updates: MS Dhoni Retires. Mohammed Shami Takes Huge Paycut In RR

IPL 2027 Retention LIVE Updates: Chennai Super Kings on Tuesday announced the appointment of the great MS Dhoni as their mentor. After 19 season, the legendary wicketkeeper-batter finally ended his playing career with CSK.

The Man Who Became Chennai: MS Dhoni's CSK Story Enters A New Chapter
Nov 17, 2026
The Man Who Became Chennai: MS Dhoni's CSK Story Enters A New Chapter

CSK on Tuesday appointed legendary wicketkeeper-batter MS Dhoni as their team mentor ahead of IPL 2027. N Srinivasan, Owner, Chennai Super Kings spoke about what MS Dhoni means to the franchise.

MS Dhoni Told CSK Owners To Release Him Ahead Of IPL 2027, Left All Stunned: "Internet Could Not Handle"
Nov 17, 2026
MS Dhoni Told CSK Owners To Release Him Ahead Of IPL 2027, Left All Stunned: "Internet Could Not Handle"

MS Dhoni's storied playing career in the IPL ended on Tuesday after he was appointed mentor of his franchise, Chennai Super Kings

IPL 2027: 5 big-ticket names whose retention could become a financial headache for their respective franchises
Nov 17, 2026
IPL 2027: 5 big-ticket names whose retention could become a financial headache for their respective franchises

The final deadline for all the franchises to submit their final list of retained and released players for IPL 2027 is 6 PM IST on November 17, barely a month from the December 16 mini auction, which is to be held in Goa.

'I played in goal for Man City - this is what Donnarumma is doing wrong and how he can put it right'
Nov 17, 2026
'I played in goal for Man City - this is what Donnarumma is doing wrong and how he can put it right'

Gianluigi Donnarumma is under the microscope at Manchester City after some high-profile errors

MS Dhoni Retires: CSK Owners' Full Statement - "The Bond Will Continue To Grow"
Nov 17, 2026
MS Dhoni Retires: CSK Owners' Full Statement - "The Bond Will Continue To Grow"

Chennai Super Kings (CSK) owner N Srinivasan and CEO Kasi Viswanathan paid tribute to MS Dhoni, after announcing his transition from player to mentor ahead of IPL 2027.

Recommended

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

About Us

Everybody can’t get enough of sports be it football, rugby, cricket even athletics. From local cup to super cup to world cup, there’s enough sports to be enjoyed every minute of every day

Copyright © 2015 - 2026 Daily Sports Club. All Rights Reserved.